Article Versions Notes

Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, et al. First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study. Cancers. 2020; 12(6):1488. https://doi.org/10.3390/cancers12061488

Schliemann, Christoph, Mirjam Gerwing, Hauke Heinzow, Saliha Harrach, Christian Schwöppe, Moritz Wildgruber, Anna A. Hansmeier, Linus Angenendt, Andrew F. Berdel, Ursula Stalmann, and et al. 2020. "First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study" Cancers 12, no. 6: 1488. https://doi.org/10.3390/cancers12061488

Schliemann, C., Gerwing, M., Heinzow, H., Harrach, S., Schwöppe, C., Wildgruber, M., Hansmeier, A. A., Angenendt, L., Berdel, A. F., Stalmann, U., Berning, B., Kratz-Albers, K., Middelberg-Bisping, K., Wiebe, S., Albring, J., Wilms, C., Hartmann, W., Wardelmann, E., Krähling, T., ... Berdel, W. E. (2020). First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study. Cancers, 12(6), 1488. https://doi.org/10.3390/cancers12061488